Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer

Authors: Joji Kitayama, Koji Yasuda, Kazushige Kawai, Eiji Sunami, Hirokazu Nagawa

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Although preoperative radiotherapy (RT) is widely used as the initial treatment for locally advanced rectal cancer (RC) in the neoadjuvant setting, factors determining clinical response have not been adequately defined. In order to find other factors possibly related with radiosensitivity, we evaluated the relationships between circulating blood cell counts and RT effects.

Methods

In 179 cases with advanced RC, we retrospectively examined hemoglobin (Hb) levels and counts of white blood cells (WBC), platelets and WBC subsets before and after RT and investigated their associations with the complete response (CR) rate together with other clinicopathological factors.

Results

The ratio of lymphocytes in WBC taken before RT was significantly greater in 15 CR cases as compared with those in non-CR cases. Patients with high lymphocyte percentages (25.7%) showed better outcome than the counterparts. Conversely, the ratio of neutrophiles was reduced in CR cases. The lymphocyte ratio showed an independent association with CR with multivariate analysis, and tended to be maintained at relatively high levels in CR cases.

Conclusions

In RC patients, peripheral blood lymphocytes have a significant impact on the CR rate in response to RT. Lymphocyte-mediated immune reactions are supposed to have positive roles on clinical response in radiotherapy for RC.
Appendix
Available only for authorised users
Literature
1.
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004, 351 (17): 1731-1740. 10.1056/NEJMoa040694.CrossRefPubMed
2.
Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006, 355 (11): 1114-1123. 10.1056/NEJMoa060829.CrossRefPubMed
3.
Ortholan C, Francois E, Thomas O, Benchimol D, Baulieux J, Bosset JF, Gerard JP: Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials. Dis Colon Rectum. 2006, 49 (3): 302-310. 10.1007/s10350-005-0263-x.CrossRefPubMed
4.
Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH: Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007, 109 (9): 1750-1755. 10.1002/cncr.22625.CrossRefPubMed
5.
Park HC, Janjan NA, Mendoza TR, Lin EH, Vadhan-Raj S, Hundal M, Zhang Y, Delclos ME, Crane CH, Das P, Wang XS, Cleeland CS, Krishnan S: Temporal Patterns of Fatigue Predict Pathologic Response in Patients Treated with Preoperative Chemoradiation Therapy for Rectal Cancer. Int J Radiat Oncol Biol Phys. 2009, 75 (3): 775-81. 10.1016/j.ijrobp.2008.11.027.CrossRefPubMedPubMedCentral
6.
Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, Fazio VW: Predictive Factors of Pathologic Complete Response After Neoadjuvant Chemoradiation for Rectal Cancer. Ann Surg. 2009, 250 (4): 582-589.PubMed
7.
Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ: Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009, 74 (1): 55-59. 10.1016/j.ijrobp.2008.07.050.CrossRefPubMed
8.
Kremser C, Trieb T, Rudisch A, Judmaier W, de Vries A: Dynamic T(1) mapping predicts outcome of chemoradiation therapy in primary rectal carcinoma: sequence implementation and data analysis. J Magn Reson Imaging. 2007, 26 (3): 662-671. 10.1002/jmri.21034.CrossRefPubMed
9.
Marquardt F, Rodel F, Capalbo G, Weiss C, Rodel C: Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol. 2009, 185 (6): 371-378. 10.1007/s00066-009-1936-5.CrossRefPubMed
10.
Kuremsky JG, Tepper JE, McLeod HL: Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009, 74 (3): 673-688. 10.1016/j.ijrobp.2009.03.003.CrossRefPubMed
11.
Kikuchi M, Mikami T, Sato T, Tokuyama W, Araki K, Watanabe M, Saigenji K, Okayasu I: High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer. 2009, 101 (1): 116-123. 10.1038/sj.bjc.6605105.CrossRefPubMedPubMedCentral
12.
Jiang SM, Wang RB, Yu JM, Zhu KL, Mu DB, Xu ZF: [Correlation of VEGF and Ki67 expression with sensitivity to neoadjuvant chemoradiation in rectal adenocarcinoma]. Zhonghua Zhong Liu Za Zhi. 2008, 30 (8): 602-605.PubMed
13.
Barcellos-Hoff MH, Park C, Wright EG: Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev Cancer. 2005, 5 (11): 867-875. 10.1038/nrc1735.CrossRefPubMed
14.
Prise KM, Schettino G, Folkard M, Held KD: New insights on cell death from radiation exposure. Lancet Oncol. 2005, 6 (7): 520-528. 10.1016/S1470-2045(05)70246-1.CrossRefPubMed
15.
Gudkov AV, Komarova EA: The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003, 3 (2): 117-129. 10.1038/nrc992.CrossRefPubMed
16.
Mothersill C, Seymour CB: Radiation-induced bystander effects--implications for cancer. Nat Rev Cancer. 2004, 4 (2): 158-164. 10.1038/nrc1277.CrossRefPubMed
17.
18.
Stone HB, Peters LJ, Milas L: Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst. 1979, 63 (5): 1229-1235.PubMed
19.
Demaria S, Formenti SC: Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol. 2007, 83 (11-12): 819-825. 10.1080/09553000701481816.CrossRefPubMed
20.
Lorimore SA, Coates PJ, Scobie GE, Milne G, Wright EG: Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects?. Oncogene. 2001, 20 (48): 7085-7095. 10.1038/sj.onc.1204903.CrossRefPubMed
21.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007, 13 (9): 1050-1059. 10.1038/nm1622.CrossRefPubMed
22.
Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, et al: Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res. 2007, 13 (5): 1493-1502. 10.1158/1078-0432.CCR-06-1772.CrossRefPubMed
23.
Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, Debucquoy A, Haustermans K, McBride WH: T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res. 2008, 14 (15): 4883-4890. 10.1158/1078-0432.CCR-07-4462.CrossRefPubMedPubMedCentral
24.
Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJ, von Blomberg BM, Scheper RJ, van den Eertwegh AJ: Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol. 2007, 25 (7): 862-868. 10.1200/JCO.2006.08.5787.CrossRefPubMed
25.
Stjernsward J, Jondal M, Vanky F, Wigzell H, Sealy R: Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma. Lancet. 1972, 1 (7765): 1352-1356. 10.1016/S0140-6736(72)91091-4.CrossRefPubMed
26.
Stratton JA, Byfield PE, Byfield JE, Small RC, Benfield J, Pilch Y: A comparison of the acute effects of radiation therapy, including or excluding the thymus, on the lymphocyte subpopulations of cancer patients. J Clin Invest. 1975, 56 (1): 88-97. 10.1172/JCI108084.CrossRefPubMedPubMedCentral
27.
O'Toole C, Unsgaard B: Clinical status and rate of recovery of blood lymphocyte levels after radiotherapy for bladder cancer. Cancer Res. 1979, 39 (3): 840-843.PubMed
28.
Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL: Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004, 10 (11): 3755-3762. 10.1158/1078-0432.CCR-04-0054.CrossRefPubMed
29.
Hicks MJ, Durie BG, Slymen DJ: Low circulating T-helper cells in relapsing multiple myeloma. J Clin Lab Anal. 1989, 3 (4): 202-208. 10.1002/jcla.1860030403.CrossRefPubMed
30.
McMillan DC, Fyffe GD, Wotherspoon HA, Cooke TG, McArdle CS: Prospective study of circulating T-lymphocyte subpopulations and disease progression in colorectal cancer. Dis Colon Rectum. 1997, 40 (9): 1068-1071. 10.1007/BF02050931.CrossRefPubMed
31.
Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC: Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009, 69 (4): 1553-1560. 10.1158/0008-5472.CAN-08-1921.CrossRefPubMedPubMedCentral
32.
Muller I, Munder M, Kropf P, Hansch GM: Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?. Trends Immunol. 2009, 30 (11): 522-530. 10.1016/j.it.2009.07.007.CrossRefPubMed
33.
Wichmann MW, Meyer G, Adam M, Hochtlen-Vollmar W, Angele MK, Schalhorn A, Wilkowski R, Muller C, Schildberg FW: Detrimental immunologic effects of preoperative chemoradiotherapy in advanced rectal cancer. Dis Colon Rectum. 2003, 46 (7): 875-887. 10.1007/s10350-004-6677-z.CrossRefPubMed
Metadata
Title
Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer
Authors
Joji Kitayama
Koji Yasuda
Kazushige Kawai
Eiji Sunami
Hirokazu Nagawa
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-64

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

The association of APE1 −656T > G and 1349 T > G polymorphisms and cancer risk: a meta-analysis based on 37 case-control studies

Research article

The hOGG1 Ser326Cys polymorphism and prostate cancer risk: a meta-analysis of 2584 cases and 3234 controls

Research article

A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis

Research article

Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines

Research article

HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop

Research article

Diet folate, DNA methylation and genetic polymorphisms of MTHFRC677T in association with the prognosis of esophageal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits